Knopp Biosciences strives to advance the treatment of devastating immunological and neurological diseases through breakthrough drug discovery. We target diseases imposing high costs on the healthcare system, with patient populations clearly identifiable using validated biomarkers or genetic testing. Knopp believes in the spirit of innovation, collaboration, and developing new medicines with exceptional safety and efficacy.
The company’s team of industry leaders in discovery research, medicinal chemistry, clinical development, and business operations has established a foundation for agility, integrity, and success in our discovery and development processes.
Knopp is also committed to expanding the drug discovery and development industry in Western Pennsylvania. The Pittsburgh area is home to some of the nation's most significant and well-funded research institutions, creating a favorable environment for the biopharma industry. Knopp plays an important role in expanding the region’s capabilities and reputation as a premier location for bioscience commercialization.
Knopp's pipeline consists of investigational drug products that have not been approved by the U.S. Food and Drug Administration. These investigational drug products are still undergoing clinical study to verify their safety and effectiveness.